
Heartflow's AI Plaque Analysis software leads to significant improvements in cholesterol management and cardiac risk reduction in coronary artery disease patients.
Key Details
- 1DECIDE Registry, the largest prospective study of its kind, enrolled ~20,000 CAD patients at 30+ US clinical sites.
- 2Heartflow AI Plaque Analysis prompted treatment changes in over 50% of patients versus CCTA alone.
- 3Patients managed using the software saw mean LDL cholesterol reductions of 18.7 mg/dL.
- 4A 15% estimated reduction in cardiac event risk was observed for these patients.
- 5Significant management changes occurred even in patients with no calcified plaque.
- 6The AI provides individualized risk insights by quantifying and characterizing all plaque types, including non-calcified, soft plaques.
Why It Matters

Source
Cardiovascular Business
Related News

Aidoc Receives FDA Breakthrough Status for Multi-Condition CT AI Triage
Aidoc has received FDA Breakthrough Device status for its AI solution that flags multiple critical conditions in CT scans.

AI Triage Cuts CT Report Turnaround for Pulmonary Embolism—Daytime Only
FDA-backed study finds AI triage tools reduce radiology CT report turnaround times for pulmonary embolism during peak hours.

BMI Significantly Impacts AI Accuracy in CT Lung Nodule Detection
New research demonstrates that high BMI negatively impacts both human and AI performance in chest low-dose CT interpretation, highlighting dataset diversity concerns.